echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Hengrui Medicine Fluzoparib Capsules and Abiraterone Acetate Tablets Clinical Trials Approved

    Hengrui Medicine Fluzoparib Capsules and Abiraterone Acetate Tablets Clinical Trials Approved

    • Last Update: 2021-07-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    On March 17, Hengrui Medicine issued an announcement stating that its subsidiary Chengdu Shengdi Medicine had recently received the "Drug Clinical Trial Approval Notice" for fluzoparil capsules and abiraterone acetate tablets (I) approved and issued by NMPA.
    And will carry out clinical trials in the near future

    .


    Hengrui Medicine's fluzoparib capsules have been approved by the National Medical Products Administration on December 11, 2020 for platinum-sensitive recurrent ovarian cancer and germline BRCA mutations (gBRCAm) that have undergone second-line and above chemotherapy.
    Treatment of patients with fallopian tube cancer or primary peritoneal cancer

    .
    In January 2021, this product was used for maintenance treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer after platinum-containing chemotherapy has achieved complete remission or partial remission.
    It has been approved by the National Medical Products Administration.
    The evaluation center is included in the priority evaluation

    .
    In addition to the treatment of platinum-sensitive recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer, the development of multiple indications of fluzoparil capsules alone or in combination with apatinib mesylate tablets is in phase III In the clinical research phase, there are also a variety of combination treatment options, including combination with abiraterone, combination with anti-PD-L1 antibody SHR-1316, and combination with temozolomide to treat a variety of solid tumors, which are already in the clinical development stage

    .


    Fluzoparil is a poly(ADP-ribose) polymerase (PARP) inhibitor that can specifically kill BRCA-mutated tumor cells

    .
    After inquiry, fluzoparib currently has similar products Olaparib (trade name Lynparza), Rucaparib (trade name Rubraca), Niraparib (trade name Zejula) and Talazoparib (trade name Talzenna) have been approved for sale in the United States.
    Olaparib (trade name Lynparza) was approved for listing in China in August 2018, under the trade name Lipzo

    .
    Domestic Zai Lab's Nirapali Tosylate Capsules (trade name Zile) was approved for marketing in China in December 2019 for platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer Maintenance treatment for adult patients after platinum-containing chemotherapy has achieved complete or partial remission

    .
    Upon inquiry, the global sales of Olaparib (trade name Lynparza), Rucaparib (trade name Rubraca) and Niraparib (trade name Zejula) in 2020 are approximately US$2.
    421 billion

    .


    Up to now, the total R&D expenses of fluzoparil-related projects have been approximately 321.
    24 million yuan

    .
    Abiraterone tablets were first developed by Janssen-Cilag International NV under the trade name Zytiga®.
    They were approved for listing in the United States in April 2011 and are currently on the market in Canada, the European Union, Japan and other countries

    .
    2015, Janssen-Cilag International NV developed abiraterone tablets in China approved the trade name Zeke?

    .
    After querying EvaluatePharma's data, the sales of abiraterone acetate tablets in 2019 were US$2.
    889 billion

    .
    Up to now, a total of RMB 14.
    29 million has been invested in research and development expenses related to abiraterone acetate tablets (I)

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.